DocWire News Editors

DocwireNews

Subodh Verma, MD, of <a href="http://www.stmichaelshospital.com/">St. Michael&#8217;s Hospital</a> and University of Toronto, talks with <a href="https://proddocwire.wpengine.com/">DocWire News</a> about the EMPA-HEART Cardiolink-6 study, the first randomized, double-blind trial investigating the effect of <a href="https://proddocwire.wpengine.com/docwire-pick/diabetes-medications-raise-amputation/">empagliflozin</a> on LV structure and function in patients with <a href="https://proddocwire.wpengine.com/tag/type-2-diabetes/">type 2 diabetes</a> and established cardiovascular disease. Dr. Verma presented the results of EMPA-HEART Cardiolink-6 at the American Heart Association 2018 Scientific Session.
Researchers included a total of 152 individuals with type 2 diabetes and a prior history of MI or coronary revascularization in the study. Participants were randomized (1:1) to receive either empagliflozin 10 mg or placebo for six months. The primary endpoints included changes in indexed LV end-systolic/diastolic volumes, LV ejection fraction, regional LV systolic/diastolic function, NT-proBNP, and troponins.
Read DocWire News&#8217; coverage of EMPA-HEART Cardiolink-6 <a href="https://proddocwire.wpengine.com/conference-coverage/american-heart-association-2018-scientific-sessions/empa-heart-empagliflozin-reversed-lv-remodeling-in-t2d-patients/">here</a>.
Read more DocWire News coverage of AHA 2028 <a href="https://proddocwire.wpengine.com/aha-2018-scientific-sessions/">here</a>.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

VIDEO: Subodh Verma, MD on EMPA-HEART Cardiolink-6

AHA Scientific Sessions 2018

Subodh Verma, MD, of St. Michael's Hospital and University of Toronto, talks with DocWire News about the EMPA-HEART Cardiolink-6 study, the first randomized, double-blind ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe